Ivosidenib, an inhibitor of IDH1 mutants, and enasidenib, an inhibitor of IDH2 mutants, are reportedly effective against relapsed and refractory acute myeloid leukaemia (AML) with IDH1 and IDH2 mutations, respectively [86,87,88]. Here, IDH1 is linked to acute myeloid leukemia.